Nucleoside News and Research

RSS
New data shows ALS-008176 drug safe and effective against RSV infection

New data shows ALS-008176 drug safe and effective against RSV infection

Scientists generate pluripotent stem cells with more stable genomes

Scientists generate pluripotent stem cells with more stable genomes

First patient enrolled in Contravir‘s FV-100 Phase 3 study to prevent shingles, shingles-associated pain

First patient enrolled in Contravir‘s FV-100 Phase 3 study to prevent shingles, shingles-associated pain

Researchers complete participants’ enrollment in Phase III trial of vaginal ring for HIV prevention

Researchers complete participants’ enrollment in Phase III trial of vaginal ring for HIV prevention

PNP Therapeutics granted FDA orphan drug designation for Gedeptin

PNP Therapeutics granted FDA orphan drug designation for Gedeptin

Taiho, Servier sign exclusive license agreement to develop and commercialize TAS-102 drug

Taiho, Servier sign exclusive license agreement to develop and commercialize TAS-102 drug

Baruch S. Blumberg Institute engaged to conduct study using ContraVir's new HBV therapeutic candidate

Baruch S. Blumberg Institute engaged to conduct study using ContraVir's new HBV therapeutic candidate

ViiV Healthcare initiates Phase III trial to evaluate dolutegravir and rilpivirine in HIV patients

ViiV Healthcare initiates Phase III trial to evaluate dolutegravir and rilpivirine in HIV patients

Study calls for effective strategies to contain potential HDV epidemic in high-risk populations

Study calls for effective strategies to contain potential HDV epidemic in high-risk populations

New simeprevir clinical data to be presented at EASL's International Liver Congress 2015

New simeprevir clinical data to be presented at EASL's International Liver Congress 2015

Recruitment completed for Phase III PROUD-PV trial of P1101 for treatment of polycythemia vera

Recruitment completed for Phase III PROUD-PV trial of P1101 for treatment of polycythemia vera

Taiho announces submission of TAS-102 MAA to EMA for treatment of mCRC

Taiho announces submission of TAS-102 MAA to EMA for treatment of mCRC

Taiho Oncology announces acceptance of TAS-102 NDA for review by FDA

Taiho Oncology announces acceptance of TAS-102 NDA for review by FDA

HIV Prevention Trials Network launches two phase 2 studies to evaluate new HIV drugs

HIV Prevention Trials Network launches two phase 2 studies to evaluate new HIV drugs

AbbVie gets European Commission's approval to market VIEKIRAX + EXVIERA for HCV treatment

AbbVie gets European Commission's approval to market VIEKIRAX + EXVIERA for HCV treatment

Using HIV drugs to treat AMD: an interview with Dr Mark Young

Using HIV drugs to treat AMD: an interview with Dr Mark Young

ContraVir granted Type B meeting with FDA to discuss proposal for FV-100 Phase 3 trial

ContraVir granted Type B meeting with FDA to discuss proposal for FV-100 Phase 3 trial

FDA approves AbbVie's VIEKIRA PAK for treatment of patients with GT1 HCV infection

FDA approves AbbVie's VIEKIRA PAK for treatment of patients with GT1 HCV infection

SLU investigators find promising candidates for new herpes virus treatments

SLU investigators find promising candidates for new herpes virus treatments

Chimerix, ContraVir collaborate to develop and commercialize antiviral drug candidate CMX157

Chimerix, ContraVir collaborate to develop and commercialize antiviral drug candidate CMX157